What is known about the risk of congenital malformations with erythromycin ethylsuccinate use during pregnancy?

Studies of major congenital malformation risk with macrolides, including erythromycin ethylsuccinate, during pregnancy give conflicting results, with some human observational studies reporting cardiovascular malformations after early-pregnancy exposure to erythromycin-containing medicines.